NanoCellect Biomedical, Inc.
Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.
Raised
$29M
Investors
32
Min Invest
None stated
Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.
What this filing shows
·Every sentence is a value as filed on SEC Form D
NanoCellect Biomedical, Inc. is a Delaware corporation that first filed a Form D on November 13, 2015 and most recently amended it on June 30, 2023 in the Biotechnology industry group. The offering claims Rule 506(b) and covers equity. NanoCellect Biomedical, Inc. reported $28,929,239 sold from 32 investors of a $38,504,239 total offering as of the Form D filed June 30, 2023. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. The issuer's address of record is 6404 Nancy Ridge Drive, San Diego, CA 92121.
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
0
none on file
Critical / warning
0 / 0
0 watch · 0 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
5
lapsed, closed
Investor
- 5 offering timelines: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Item 3 changed on the Form D filed 2023-06-30: 0 related persons added and 3 removed against the filing of 2021-08-27; 5 now listed. The names are in the Terminal feed.
Jose Morachis
Executive Officer · SAN DIEGO, CA
Paul Conley
Director · San Diego, CA
Jeremy Baker
Executive Officer · San Diego, CA
Chris Neary
Executive Officer, Director · San Diego, CA
Nicolas Barthelemy
Director · San Diego, CA
Questions About NanoCellect Biomedical, Inc.
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is NanoCellect Biomedical, Inc.?
NanoCellect Biomedical, Inc. is a Delaware corporation that filed a Form D with the SEC on June 30, 2023 in the Biotechnology industry group. The filing claims Rule 506(b) for an offering of equity.
Is NanoCellect Biomedical, Inc. legit?
AltStreet does not rate legitimacy; it reports the public record. NanoCellect Biomedical, Inc. filed a Form D with the SEC on June 30, 2023 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $28,929,239 sold to 32 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is NanoCellect Biomedical, Inc. registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that NanoCellect Biomedical, Inc. claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has NanoCellect Biomedical, Inc. raised?
NanoCellect Biomedical, Inc. reported $28,929,239 sold from 32 investors of a $38,504,239 total offering as of the Form D filed June 30, 2023.
Who can invest in NanoCellect Biomedical, Inc.?
The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.
What is the minimum investment in NanoCellect Biomedical, Inc.?
The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.
Who is selling NanoCellect Biomedical, Inc. and how are they paid?
The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly.
Who is behind NanoCellect Biomedical, Inc.?
The Form D lists 5 related persons: Jose Morachis, executive officer; Paul Conley, director; Jeremy Baker, executive officer; Chris Neary, executive officer, director; Nicolas Barthelemy, director. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is NanoCellect Biomedical, Inc. located?
The issuer's address on its SEC filings is 6404 Nancy Ridge Drive, San Diego, CA 92121. Its phone number of record is 9519664963. It is organized under the laws of Delaware.
How long is the NanoCellect Biomedical, Inc. offering open?
The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 2 amendments are on record for this CIK.
What is NanoCellect Biomedical, Inc.'s revenue?
The issuer declined to disclose its revenue range on the Form D, which the form permits.
Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.